Actinium Pharma opening the door to transplant therapy

16 August 2018

The positive outcome from the data monitoring committee reflects the good progress being made by Actinium Pharmaceutical's (NYSE: ATNM) lead product Iomab-B in the SIERRA pivotal trial in relapsed/refractory acute myeloid leukemia (R/R AML).

On schedule to deliver top-line data in second-half 2019E, Iomab-B looks set to open the door to potentially curative stem cell therapy in a large cohort of patients with otherwise limited effective treatment options, says Goetzpartners securities research analyst Dr Chris Redhead.

First Phase II data from Actinium's Actimab program should provide a further near term catalyst in second-half 2018E. Goetzpartners reiterates and maintains its ‘Outperform’ recommendation and target price of $4.00/share as detailed in our initiation report of April 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK